14 publications
Name | Date | Type | Actions |
---|---|---|---|
2010 annual earnings Lure (France), April 4, 2011 – Vétoquinol’s Board of Directors, meeting on March 18, 2011, has reviewed the Group’s business and approved its 2010 financial statements. |
04/04/2011 | Public releases | |
2010 Revenues grow 11.8%, driven by organic growth The Vétoquinol Group reports sustained sales growth driven by its “hybrid” business model, supported by a sound level of organic growth. |
25/01/2011 | Public releases | |
2011 Half Year Results 2011 Half year results |
31/08/2011 | Half Year Report | |
European launch of new Nsaid Cimalgex® Lure (France), June 14, 2011 – Vetoquinol announces the European launch of CIMALGEX®, a new treatment for pain and inflammation in dogs. |
14/06/2011 | Public releases | |
Forcyl®: european launch of new drug Lure (France), September 29, 2011 – Vétoquinol announces the European launch of Forcyl®, a new drug based on 16% concentrated marbofloxacin allowing the treatment of cattle respiratory infections with a single injection. |
29/09/2011 | Public releases | |
International expansion and new product launches Lure (France), July 19, 2011 – Vétoquinol Group sales rose to €139.7 million in the first six months of 2011. |
19/07/2011 | Public releases | |
Jacques du Puy appointed Vétoquinol Managing Director Lure (France), October 12, 2011 – The Vétoquinol Group announces the appointment |
12/10/2011 | Public releases | |
Net Sales rise 3% to €66.4 Million in the first Quarter of 2011 The Vétoquinol group reported a 3.0% rise in first quarter 2011 net sales to €66.4 million, compared to the same period last year. |
19/04/2011 | Public releases | |
Q3 2011 Sales Vétoquinol achieved Q3 2011 sales of €68.4 million, in line with the previous year. |
25/10/2011 | Public releases | |
Rapport financier semestriel 2011 (french) > Rapport d’activité semestriel 2011 |
01/09/2011 | Half Year Report |